Wikipedia

Amanda Feilding

Amanda Claire Marian Charteris, Countess of Wemyss and March (née Feilding; born 30 January 1943), also known as Amanda Feilding, is an English drug policy reformer, lobbyist,[2] and research coordinator. In 1998, she founded the Foundation to Further Consciousness, later renamed to the Beckley Foundation,[3] a charitable trust which initiates, directs, and supports neuroscientific and clinical research into the effects of psychoactive substances on the brain and cognition. She has also co-authored over 50 papers published in peer-reviewed journals, according to the Foundation.[4] The central aim of her research is to investigate new avenues of treatment for such mental illnesses as depression, anxiety, and addiction, as well as to explore methods of enhancing well-being and creativity.

Amanda Feilding
Born
Amanda Claire Marian Feilding

(1943-01-30) 30 January 1943 (age 81)[1]
NationalityBritish
Other namesLady Neidpath
Occupation(s)Drug policy reformer, neuroscience researcher
Known forBeckley Foundation
Notable workHeartbeat in the Brain
TitleCountess of Wemyss and March (since 2008)
Spouse
​
​
(m. 1995)​
Children2 sons (with Joseph Mellen)

Feilding has been a proponent of utilising the cognitive effects of cannabis since the 1960s. She has experimented with trepanning, drilling a hole into the skull to expose the dura mater, a technique used in some cultures to treat mental illness, and considered by some to provide a calming effect or a higher state of consciousness.[3]

Feilding is also a proponent of the use of LSD to trigger long-term improvements in creativity.[5]

Feilding received the Women's Entrepreneurship Day Organization’s Science Pioneer Award at the United Nations in 2022. The award, also recognised by the US Congress, highlights women entrepreneurs.[6][better source needed]

Early life and experiments

edit

Born in 1943, Feilding is the youngest child of Basil Feilding (great-grandson of the 7th Earl of Denbigh and of the 3rd Marquess of Bath) and his wife, Margaret Feilding, who was his second cousin. She grew up in Oxfordshire at Beckley Park, a Tudor hunting lodge with three towers and three moats, which was owned by her father and situated on the edge of a fen outside Oxford.

From an early age, Feilding was interested in states of consciousness and mysticism. At 16 years old, with just £25 in her pocket, she embarked on a journey to Ceylon (now Sri Lanka), where her godfather, Bertie Moore, had become a Buddhist monk.[2] Although she did not reach Ceylon, Feilding hitchhiked as far as the Syrian border, where she spent time living with Bedouins before returning to the UK.[2] Feilding then studied Comparative Religions and Mysticism with Professor R.C. Zaehner, and Classical Arabic with Professor Albert Hourani.[7] She concentrated later on learning about altered states of consciousness, psychology, physiology and, later, neuroscience.

Feilding had her first psychedelic experience at 22 years of age, when an acquaintance spiked her coffee with a massive dose of then-legal LSD.[7] The experience nearly broke her, and she retreated to her family home for months to recover.

Feilding gained notoriety in 1970 when she performed trepanation on herself, with a dental drill.[3] She made a short art film about the experience, entitled Heartbeat in the Brain. The 1998 documentary A Hole in the Head contains footage from Heartbeat in the Brain.[8] Feilding also began to microdose herself with LSD while she was in her 20s. A 2019 Guardian article offers this analysis: "It would be fair to say ... that her credibility as an advocate has not always been helped by her storied history with self-experimentation".[2]

Trepanation was part of her exploration into the effects of different techniques to alter and enhance consciousness. During this period, she wrote Blood and Consciousness, which hypothesized that changing ratios of blood and cerebrospinal fluid underlie changes in consciousness, and also described the theory of the "ego" as a conditioned reflex mechanism that controls the distribution of blood in the brain.[9]

Beckley Foundation

edit

In 1998, Feilding founded the Foundation to Further Consciousness, later renamed Beckley Foundation, a charitable trust[3] which claims to promote a rational,[citation needed] evidence-based approach to global drug policies and initiates, directs, and supports pioneering neuroscientific and clinical research into the effects of psychoactive substances on the brain and cognition. The central aim of her research is to investigate new avenues of treatment for such mental illnesses as depression, anxiety, and addiction, as well as to explore methods of enhancing well-being and creativity.[3] The Foundation states that Fielding has co-authored over 50 scientific papers in peer-reviewed journals.[4] Feilding is the Founder and executive director of the Foundation.[10]

Through the Beckley Foundation, Feilding initiates, directs, and, supports scientific research investigating psychoactive substances, such as cannabis and other psychedelics (LSD, psilocybin, ayahuasca, DMT, 5-MeO-DMT, and MDMA, commonly known as Ecstasy).[11]

Considered one of the pioneers of the renaissance of psychedelic research, with the New Scientist calling her the "Queen of Consciousness",[12][13] she has initiated several ground-breaking research projects. Of note is a study investigating the efficacy of using psilocybin as an aid to psychotherapy in overcoming depression[14] and nicotine addiction,[15] a brain imaging study investigating the effects of psilocybin and MDMA on cerebral blood supply,[16] an examination of the effects of cannabis on creativity[17] and of the importance of the THC/CBD ratio in mental health,[18] and the first brain imaging study investigating the effects of LSD on the brain.[19]

Feilding has also been active in drug policy reform and was among the first to start building an evidence-base upon which new policies could be formed, arguing that benefits as well as harms should be considered. In 2007, Feilding convened the Global Cannabis Commission, producing a report authored by a group of leading drug policy analysts,[20] which lays out a plan for possible reforms of cannabis control policies at national and international levels. 2011 saw Feilding bring together members of the Global Commission on Drug Policy Reform (a panel of world leaders and intellectuals) and political leaders from 14 countries interested in reform. Together, at the House of Lords, they launched the Beckley Foundation Global Initiative for Drug Policy Reform, a joint initiative with the All Party Parliamentary Group on Drug Policy Reform, which was set up to support the BF's initiative to drive forward alternative approaches to drug control to create more humane, evidence-based policies that would reduce the potential harm of drugs to individuals and societies.

From these meetings, two important reports were written and published. The first, in 2012, was entitled 'Roadmaps to Reforming the UN Drug Conventions'.[21] It detailed ways in which the UN drug conventions could be amended to give countries greater freedom to adopt policies better suited to their individual needs. The next, in 2013, was a rigorous academic analysis by the widely respected Institute for Social and Economic Research.[22] It discussed the possible outcomes of decriminalising and regulating cannabis in England and Wales. Also in 2013, President Otto Perez Molina of Guatemala asked Feilding to advise on the Guatemala government's policy on drugs, and in 2015, Mark Golding, the Jamaican Minister of Justice, invited Feilding to advise him and the government in developing plans for the country's new system of cannabis regulation. In May 2016, in response to the enforcement of the Home Office's Psychoactive Substance Act, the Beckley Foundation published a chapter on the regulation of new psychoactive substances (NPS) from an upcoming report entitled Roadmaps to Regulation: Cannabis, Psychedelics, MDMA and NPS.[23]

Continued LSD research

edit

A report in early 2019 indicated that the Foundation would be conducting further research into the use of LSD to trigger long-term improvements in creativity. (A previous study by the Beckley/Imperial Research Programme, in conjunction with Imperial College, indicated some likelihood of success in this goal, according to Feilding.)[12] Feilding offered this summary of the new plan.[5]

Participants will receive two microdoses (10 mic) per week over a period of four weeks. On each microdosing day, they will complete questionnaires to assess various aspects of their mood, wellbeing and cognitive functions as well as other tests, including a computerized Go game, to investigate creativity and intuitive thinking. Brain function will be measured using EEG both at rest and while participants are actively involved in those tests. Importantly, this study will also evaluate the safety and tolerability of repeated microdoses of LSD, via measures of LSD pharmacokinetics and pharmacodynamics, including physiological markers of inflammation and neurogenesis.

Beckley Canopy Therapeutics

edit

News reports in 2018-2019 indicated that the Foundation had been retained by the Canadian cannabis producer Canopy Growth Corporation to conduct research as to the benefits of various strains of its products, particularly in treating pain, anxiety and drug addiction. One goal is to reduce dependence on opioids in treating cancer-related pain. The two formed Beckley Canopy Therapeutics in Oxford, to raise funds from investors for cannabinoid research and drug development.

Canopy Growth has been planning to export its products to the UK.[24] The long-term intent of the partnership is to confirm the value of cannabis in specific conditions and to convince insurers to pay for medical cannabis when used accordingly. Mark Ware, Canopy's chief medical officer, said in an interview that Feilding's "ability to take a scientific look at what would otherwise be considered as controversial therapeutics makes her a very good partner".[3]

Feilding's son, Cosmo Feilding Mellen, is the managing director of the partnership.[25][3]

Personal life

edit

In 1966, Feilding met and formed a relationship with Dutch scientist Bart Huges. From the late 1960s, she lived with Joseph Mellen, with whom she had two sons.[26]

Feilding and Mellen separated in the mid-1990s. On 29 January 1995, she married James Charteris, 13th Earl of Wemyss and 9th Earl of March (then known by the courtesy title of Lord Neidpath),[27] under the Bent Pyramid in Egypt.[26] Feilding also uses the title of Lady Neidpath.[28]

When discussing how her mother viewed her life when Feilding was in her 30s, she made this comment during an interview: "There I was, druggy, trepanned, unmarried, with two sons – bastards, as she might have seen them – and she didn’t mind a bit".[2]

Feilding works at Beckley Park, a former Tudor hunting lodge near the village of Beckley, Oxfordshire.[29] As of early 2019, the property housed the offices of five researchers and interns.[12] Some news articles refer to Beckley Park as her residence, but Feilding and her husband maintain an official residence at Stanway House in Gloucestershire and also own Gosford House in East Lothian.[30][31]

In 2014, Feilding sold a version of the Chardin painting Le Bénédicité from the collection at Gosford House. It was attributed to the school of Chardin and sold for £1.15M. A subsequent examination revealed Chardin's signature, leading to its reattribution as the second known example in Chardin's own hand. It was resold for $10.5m (£8.5m) in January 2015. Feilding unsuccessfully sued the original dealer for negligence.[32]

Trepanation

edit

Feilding learned about the ancient practice of trepanation from Bart Huges, whom she met in 1966, and who published a scroll on the topic.[33] The hypothesis that she investigated proposes that trepanation improves cerebral circulation by allowing the "full heartbeat" to express itself inside the cranial cavity, which Feilding hypothesises cannot fully occur after the closing of the cranial bones in adulthood. To compensate for the relative loss of blood in the brain, she hypothesised that humans developed an internal system of control of blood flow in the brain, which Feilding identifies with the development of the "ego" and the origins of language.[34] Trepanation, Feilding hypothesises, allows increased blood circulation, allowing people to achieve and sustain a slightly higher state of consciousness that she theorises children experience before their cranial bones fuse. Recent research on patients with cranial lesions in collaboration with Prof. Yuri Moskalenko has provided evidence of blood flow changes. This is part of an investigation on the change of intracranial dynamics with age, and ways to increase cranial compliance (which, they theorise, might help limit the detrimental changes associated with ageing).[35]

Although Feilding believes that trepanation can expand consciousness and reduce neurosis, the practice has gained no support from the medical community over the years.[2]

Feilding ran for British Parliament twice, in 1979 and 1983, on the platform 'Trepanation for the National Health' with the intention of advocating research into its potential benefits; she advocated the provision of the procedure by the National Health Service.[3]

Selection of articles

edit

Feilding has co-authored a number of papers and reports with the Beckley Foundation.

Scholarly articles

edit
  • Carhart-Harris RL, ..., Feilding A, Nutt DJ (2016). Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences, 113(17), 4853–4858.
  • Carhart-Harris RL, ..., Feilding A, Nutt DJ (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry, 3(7), 619–627.
  • Lebedev AV, ..., Feilding A, Nutt DJ, Carhart-Harris RL (2016). LSD-induced entropic brain activity predicts subsequent personality change. Human Brain Mapping, 37(9), 3203–3213.
  • Tagliazucchi E, ..., Feilding A, Nutt DJ, Carhart-Harris RL (2016). Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution. Current Biology, 26(8), 1043–1050.
  • Soler J, Elices M, Franquesa A, Barker S, Friedlander P, Feilding A, Pascual JC, Riba J (2016). Exploring the therapeutic potential of ayahuasca: acute intake increases mindfulness-related capacities. Psychopharmacology, 233(5), 823–829.
  • Roseman L, Leech R, Feilding A, Nutt DJ, & Carhart-Harris RL (2014). The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Frontiers in human neuroscience, 8, 204.
  • Carhart-Harris RL, ..., Feilding A, & Nutt DJ (2014). The Effects of Acutely Administered 3, 4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level–Dependent Resting State Functional Connectivity. Biological psychiatry, S0006-3223(14)00005-5
  • Schafer G, Feilding A, Morgan CJ, Agathangelou M, Freeman TP, & Curran HV (2012). Investigating the interaction between schizotypy, divergent thinking and cannabis use. Consciousness and Cognition, 21(1), 292–298.

Policy reports

edit
  • Room, Robin; Fischer, Benedikt; et al. (2008). "Cannabis Policy: Moving Beyond Stalemate". Beckley Foundation. September.
  • Room, Robin (2012). “Roadmaps to Reformation: The UN Drug Conventions”. Beckley Foundation.
  • Bryan, M; et al. (2013). "Licensing and regulation of the cannabis market in England and Wales: Towards a cost-benefit analysis”. Beckley Foundation.
  • Feilding, A and Singleton, N. (2016). "Roadmaps to Regulation: New Psychoactive Substances”. Beckley Foundation.
  • Moore K, Wells H, Feilding A (2019). "Roadmaps to Regulation: MDMA". Beckley Foundation

See also

edit

References

edit
  1. ^ "Amanda Claire Marian Charteris". Companies House. Retrieved 28 September 2021.
  2. ^ a b c d e f "Amanda Feilding: 'LSD can get deep down and reset the brain – like shaking up a snow globe'". The Guardian. 10 February 2019. Retrieved 3 April 2019.
  3. ^ a b c d e f g h "The Countess of Cannabis". Bloomberg News. 1 April 2019. Retrieved 2 April 2019.
  4. ^ a b "First Cannabis Clinical Trials All Set In UK". Cannabis Industry Journal. 19 December 2018. Retrieved 2 April 2019. In 1998, Amanda Feilding set up the Beckley Foundation, a charitable trust which initiates, directs and supports neuroscientific and clinical research into the effects of psychoactive substances. She has also co-authored over 50 scientific papers in peer-reviewed journals.
  5. ^ a b "The Beckley Foundation Intends to Study Links Between Microdosing LSD and Creativity". Forbes. 26 February 2018. Retrieved 2 April 2019. I strongly suspect LSD, and other psychedelics if used responsibly, have the potential to enhance creativity. The brain imaging studies we carried out through the Beckley/Imperial Research Programme showed a remarkable increase in connectivity throughout the brain under LSD and psilocybin, which with further research may well prove to be linked with mental flexibility and enhanced creative thought.
  6. ^ Grace Meng (NY). "WOMEN’S ENTREPRENEURSHIP DAY 2022". Congressional Record 117: 178 (November 17, 2022). p. E1163. https://www.congress.gov/117/crec/2022/11/17/168/178/CREC-2022-11-17-pt1-PgE1163-4.pdf
  7. ^ a b Simon, Matt (15 February 2018). "Inside the Mind of the Countess of Psychedelic Science". Wired. ISSN 1059-1028. Retrieved 18 July 2019.
  8. ^ Sirius, R. U. (25 August 2010). "Fixing A Hole in the Head". h+.
  9. ^ "IISG | International Institute of Social History".
  10. ^ Corporation, Canopy Growth. "Global Cannabis Research Leaders Beckley Foundation and Canopy Health Innovations Partner to Form Beckley Canopy Therapeutics". www.newswire.ca. Retrieved 15 April 2019.
  11. ^ "The Foundation". The Beckley Foundation. 29 March 2016. Retrieved 20 April 2017.
  12. ^ a b c "Amanda Feilding: 'LSD can get deep down and reset the brain – like shaking up a snow globe'". The Guardian. 10 February 2019. Retrieved 2 April 2019.
  13. ^ "The Queen of Consciousness – Amanda Feilding interviewed for the New Scientist". archive.beckleyfoundation.org. Retrieved 20 April 2017.
  14. ^ Carhart-Harris, Robin L; Bolstridge, Mark; Rucker, James; Day, Camilla M J; Erritzoe, David; Kaelen, Mendel; Bloomfield, Michael; Rickard, James A; Forbes, Ben (1 July 2016). "Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study". The Lancet Psychiatry. 3 (7): 619–627. doi:10.1016/S2215-0366(16)30065-7. ISSN 2215-0366. PMID 27210031.
  15. ^ Johnson, Matthew W.; Garcia-Romeu, Albert; Cosimano, Mary P.; Griffiths, Roland R. (1 November 2014). "Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction". Journal of Psychopharmacology. 28 (11): 983–992. doi:10.1177/0269881114548296. ISSN 1461-7285. PMC 4286320. PMID 25213996.
  16. ^ Roseman, Leor; Leech, Robert; Feilding, Amanda; Nutt, David J.; Carhart-Harris, Robin L. (1 January 2014). "The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers". Frontiers in Human Neuroscience. 8: 204. doi:10.3389/fnhum.2014.00204. ISSN 1662-5161. PMC 4034428. PMID 24904346.
  17. ^ Schafer, Gráinne; Feilding, Amanda; Morgan, Celia J. A.; Agathangelou, Maria; Freeman, Tom P.; Valerie Curran, H. (1 March 2012). "Investigating the interaction between schizotypy, divergent thinking and cannabis use". Consciousness and Cognition. 21 (1): 292–298. doi:10.1016/j.concog.2011.11.009. ISSN 1090-2376. PMC 3657189. PMID 22230356.
  18. ^ Englund, Amir; Morrison, Paul D.; Nottage, Judith; Hague, Dominic; Kane, Fergus; Bonaccorso, Stefania; Stone, James M.; Reichenberg, Avi; Brenneisen, Rudolf (1 January 2013). "Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment". Journal of Psychopharmacology. 27 (1): 19–27. doi:10.1177/0269881112460109. ISSN 1461-7285. PMID 23042808. S2CID 9087681.
  19. ^ Carhart-Harris, Robin L.; Muthukumaraswamy, Suresh; Roseman, Leor; Kaelen, Mendel; Droog, Wouter; Murphy, Kevin; Tagliazucchi, Enzo; Schenberg, Eduardo E.; Nest, Timothy (26 April 2016). "Neural correlates of the LSD experience revealed by multimodal neuroimaging". Proceedings of the National Academy of Sciences. 113 (17): 4853–4858. Bibcode:2016PNAS..113.4853C. doi:10.1073/pnas.1518377113. ISSN 0027-8424. PMC 4855588. PMID 27071089.
  20. ^ "Report of the Global Cannabis Commission". The Beckley Foundation. 15 May 2008. Retrieved 20 April 2017.
  21. ^ "Roadmaps to Reforming the UN Drug Conventions". The Beckley Foundation. 15 May 2012. Retrieved 20 April 2017.
  22. ^ Pudney, Stephen; Bryan, Mark; DelBono, Emilia (15 September 2013). "Licensing and regulation of the cannabis market in England and Wales: Towards a cost-benefit analysis". {{cite journal}}: Cite journal requires |journal= (help)
  23. ^ "Roadmaps to Regulation: New Psychoactive Substances". The Beckley Foundation. 20 May 2016. Retrieved 20 April 2017.
  24. ^ "First Cannabis Clinical Trials All Set In UK". Cannabis Industry Journal. 19 December 2018. Retrieved 2 April 2019. Beckley Canopy Therapeutics, based in Oxford, England has raised £7.4 million for the purposes of cannabinoid research and drug development. The new company is a unique partnership established between Canopy Growth Corporation and the Beckley Foundation, a research institute which examines the utilization of psychotropic drugs for the treatment of physical and mental conditions. Studies focusing on the use of cannabinoids for the treatment of opioid addiction and cancer pain will be conducted in Europe, the UK and the US. .. This is exactly the kind of high-placed, societally influential effort in other words, that might finally break the medical taboo at the most important remaining logjam– at the point of prescription and approval for patients.
  25. ^ "Beckley Canopy Therapeutics raises £7.4m for cannabis R&D". PharmaForum. 4 December 2018. Retrieved 2 April 2019. As a new business partnership investing in UK medicine and research, we would like the government to ensure that access to medicinal cannabis is as simple and straightforward as possible for patients.
  26. ^ a b "The psychedelic Countess on a mushroom mission to free your mind". London Evening Standard. 15 April 2013. Retrieved 3 July 2017.
  27. ^ Will successor to Gosford toe the line?, Sandra Dick, The Scotsman, 20 January 2009, accessed 19 March 2018
  28. ^ "Amanda Neidpath". brainbloodvolume.com. Retrieved 2 July 2017.
  29. ^ "A trip with the acid countess: Amanda Feilding and the medical case for drugs reform". www.newstatesman.com. 27 February 2019. Retrieved 15 April 2019.
  30. ^ "The Beckley Foundation". 4 March 2016.
  31. ^ Tatler http://www.tatler.com/the-tatler-list/w/earl-of-wemyss-and-march Archived 2 August 2016 at the Wayback Machine
  32. ^ "Art dealer's sale of aristocrat's French masterpiece was not negligent, court rules". City AM. 4 December 2022. Retrieved 13 December 2022.
  33. ^ "Permanently 'Stoned' | IISH". socialhistory.org. Retrieved 20 April 2017.
  34. ^ "Mind States II Program". matrixmasters.com. Retrieved 25 April 2017.
  35. ^ Moskalenko, Yu E.; Weinstein, G. B.; Kravchenko, T. I.; Mozhaev, S. V.; Semernya, V. N.; Feilding, A.; Halvorson, P.; Medvedev, S. V. (1 May 2008). "The effect of craniotomy on the intracranial hemodynamics and cerebrospinal fluid dynamics in humans". Human Physiology. 34 (3): 41–48. doi:10.1134/S0362119708030055. ISSN 0362-1197. PMID 18677946. S2CID 10878144.

https://www.ft.com/content/413af6e6-0344-4567-94ee-1cba0a21e462 Financial Times. 28 April 2023.

edit
Retrieved from "https://en.wiki.x.io/w/index.php?title=Amanda_Feilding&oldid=1245082412"